#yuhancorporation — Public Fediverse posts
Live and recent posts from across the Fediverse tagged #yuhancorporation, aggregated by home.social.
-
Yuhan Corporation secures 88.8 billion won contract with Gilead Sciences for additional supply of HIV treatment API, expanding on previous 107.7 billion won deal
#YonhapInfomax #YuhanCorporation #GileadSciences #HIVTreatment #APISupply #PharmaceuticalContract #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=64398 -
ImmuneOncia, Yuhan Corporation's immune-oncology subsidiary, lists on KOSDAQ, aiming for growth through technology transfers and clinical advancements in cancer treatments.
#YonhapInfomax #ImmuneOncia #YuhanCorporation #KOSDAQListing #ImmuneCancerDrugs #TechnologyTransfer #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=63799 -
Yuhan Corporation announces plans to acquire 20 billion won in treasury shares and cancel 25.3 billion won worth, aiming to boost shareholder value
#YonhapInfomax #YuhanCorporation #TreasuryShares #ShareholderValue #ShareCancellation #CorporateFinance #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=62942 -
Yuhan Corporation announces decision to cancel 240,627 ordinary shares worth 25.3 billion won to enhance shareholder value, with cancellation scheduled for May 23rd.
#YonhapInfomax #YuhanCorporation #ShareCancellation #ShareholderValue #TreasuryShares #CorporateAction #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=62933 -
Yuhan Corporation reports Q1 operating profit of 8.6 billion won, falling short of market expectations despite year-on-year growth, as sales reach 469.4 billion won
#YonhapInfomax #YuhanCorporation #Q1Earnings #OperatingProfit #MarketExpectations #PharmaceuticalIndustry #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=62246 -
Yuhan Corporation reports lower-than-anticipated Q1 operating profit of 8.6 billion won, signaling potential challenges in the pharmaceutical sector
#YonhapInfomax #YuhanCorporation #Q1Earnings #OperatingProfit #PharmaceuticalSector #FinancialPerformance #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=62244 -
Yuhan Corporation maintains zero-borrowing policy for 5 years, but consolidated debt rises 300 billion won due to subsidiary financing for R&D
#YonhapInfomax #YuhanCorporation #ZeroBorrowing #SubsidiaryFinancing #ResearchAndDevelopment #CashFlow #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=58525 -
Yuhan Corporation's lung cancer drug Leclaza combination therapy receives approval as first-line treatment in Japan, marking significant milestone for Korean pharmaceutical industry
#YonhapInfomax #YuhanCorporation #Leclaza #LungCancerDrug #JapanApproval #FirstLineTreatment #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=56147 -
Yuhan Corporation CEO Jo Wook-je pledges to enhance shareholder value, highlighting FDA approval for Leclaza and record-breaking net sales at annual shareholders' meeting
#YonhapInfomax #YuhanCorporation #ShareholderValue #Leclaza #FDAApproval #NetSales #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=54972